Ecuador and Andean Community Classification: Independent Determination Requirement

1. Key takeaways

In Ecuador the risk class of a device must be determined independently by ARCSA under its own instructivo; classification conclusions from other countries, including Andean Community member states, can serve only as a starting point for reference and cannot be used as the basis of a submission. Article 22 of the new regulation together with general provision TERCERA establishes this two-layer structure of independent determination aligned with international rules. Inserting a foreign classification directly into the application form is a high-frequency cause of deficiency notices and rework.

2. Legal basis

Verification note: this article cites official regulatory sources only on the Ecuadorian side. For the class systems, validity periods and holding rules of other national agencies, GRZAN has not obtained official source texts for item-by-item verification; the comparisons given are for practical estimate reference only and do not serve as a submission basis.

3. Expert insights

Insight one: the independent determination duty comes from the instructivo as a legal form. Article 22 states that ARCSA will apply the corresponding instructivos, and instructivos are issued and updated by ARCSA itself. This creates a closed determination system in which external conclusions have no automatic effect. Although general provision TERCERA adopts GHTF and IMDRF rules, it also provides that ARCSA may update the classification rules in light of technical progress and the recommendations of internationally recognized organizations, so the updating power stays with ARCSA.

Insight two: the recognition in Articles 31 and 32 and classification are two different matters, and this is the combination most often misread. Article 31 recognizes registration certificates or equivalent documents issued by highly regulated agencies as a form of evidence used for the simplified procedure; Article 32, however, expressly requires that the device must be classified by ARCSA as Class I, II, III or IV. Even on the simplified pathway, classification is made independently by ARCSA.

Insight three: what can be reused is the evidence, not the conclusion. Article 20 lists the sources of normative documents as WHO guidelines or technical reports, GHTF and IMDRF documents, the ARCSA classification instructivo, and official documents issued by other international reference regulatory agencies. These may support the classification argument, but the argument itself must still be completed within the Ecuadorian submission system.

Insight four: one condition of the simplified pathway is marketing in an IMDRF Management Committee member jurisdiction. Article 32 requires that the device be commercialized in a member jurisdiction of the IMDRF Management Committee and that the registration or authorization obtained was granted in the capacity of a medical device. This further confirms that foreign evidence opens the simplified channel but does not replace the substantive determination by ARCSA.

Insight five: the cost of a classification error is rework across the entire chain. The risk class determines which items of the technical documentation in Article 24 apply, since many requirements apply by type and class; a wrong class makes the whole dossier structure wrong, and Article 11 prohibits changing entries after submission, so rework means resubmitting and paying the fees again.

Practical estimate note: the industry often places the Ecuadorian system (I/II/III/IV) alongside the Colombian INVIMA system (I/IIa/IIb/III). Such comparison helps avoid dossier rework, but the classification conclusions of the two countries must each be made independently and cannot substitute for one another.

4. Practical recommendations

1. Use foreign classification conclusions only as the starting point of self-assessment: a written independent Ecuadorian determination must be produced.
2. For borderline products at the Class II and Class III boundary, obtain written pre-confirmation from ARCSA through the local representative: keep the reply as the basis of dossier assembly.
3. Prepare classification argumentation in parallel with any simplified-pathway submission: do not assume that recognized evidence replaces classification.
4. Lock the class before assembling the technical dossier, then determine the required items under the Article 24 matrix.
5. Run version management of classification conclusions: re-evaluate existing products whenever the ARCSA instructivo is updated.

5. Verification checklist

• □ The independent Ecuadorian classification determination has been completed and documented in writing
• □ The applicable ARCSA classification instructivo version has been obtained and archived
• □ Written pre-confirmation for borderline products has been obtained, where applicable
• □ Classification argumentation has been prepared in parallel for simplified-pathway submissions
• □ The Article 24 submission items have been set against the locked risk class
• □ Version management and updating of classification conclusions have been established

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation